Group 1 - The core point of the article is that Ruizhi Pharmaceutical (SZ 300149) held its sixth board meeting on August 28, 2025, to review the semi-annual report and related documents [1] - For the fiscal year 2024, the revenue composition of Ruizhi Pharmaceutical is 99.03% from pharmaceutical research and development services and production outsourcing, while other businesses account for 0.97% [1] - As of the report, the market capitalization of Ruizhi Pharmaceutical is 6.2 billion yuan [1]